BIOGRAPHICAL SKETCH
Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. DO NOT EXCEED FOUR PAGES.
NAME
POSITION TITLE
Alexander V. Kabanov
Professor, University of Nebraska Medical Center
(UNMC)
eRA COMMONS USER NAME
KABANOV.ALEXANDER
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)
DEGREE
(if applicable)
YEAR(s)
Faculty of Chemistry, Moscow State University
(MSU), Russia
M.S.
1979-1984
Chemistry
Department of Chemical Enzymology, MSU, Russia
Ph.D.
1984-1987
Chemical Kinetics and
Catalysis
INSTITUTION AND LOCATION
FIELD OF STUDY
A. Positions and Honors
1987-1990
Research Fellow, Department of Chemical Enzymology, MSU, Moscow, USSR
1988-1990
Head, Laboratory of Biopolymers, Institute of Applied Molecular Biology, Moscow, USSR
1990-1991
Senior Research Fellow, Department of Chemical Enzymology, MSU
1991-1993
Head, Department of Biopolymers, National Research Center of Molecular Diagnostics and
Therapy (former Institute of Applied Molecular Biology), Moscow, Russia
1991-1997
Leading Research Fellow, Department of Chemical Enzymology, MSU
1994-2001
Associate Professor, College of Pharmacy, UNMC, Omaha, NE
1995-Present Member, UNMC Eppley Cancer Center, Omaha, NE
2001-Present Professor of Pharmaceutical Sciences, College of Pharmacy, UNMC
2001-Present Professor (courtesy), Eppley Institute for Research in Cancer and Allied Diseases, UNMC
2002-Present Professor (adjunct), Faculty of Chemistry, MSU
2004-Present Parke-Davis Endowed Chair in Pharmaceutics, College of Pharmacy, UNMC
2004-Present Director, Center for Drug Delivery and Nanomedicine (CDDN), UNMC
2005-Present Professor (courtesy), Department of Genetics, Cell Biology and Anatomy, UNMC
2007-Present Professor (courtesy), Pharmacology and Experimental Neuroscience, UNMC
Honors & Awards/Advisory Functions: 1988 Lenin Komsomol Prize; 1990 Doctor of Sciences (Chemistry and
Biochemistry), MSU; 1995 National Science Foundation (NSF) CAREER award; 2003 NSF Special Creativity
Award; 2006 UNMC Distinguished Scientist; 2007 University of Nebraska Outstanding Research and Creative
Activity (ORCA) award; 2003-06 (elected) member Board of Scientific Advisors for Controlled Release Society
(CRS); 2007 Bioactive Materials Program Chair for 34th CRS Annual Meeting; 2003-2006 member, Non-viral
Gene Transfer Vectors Committee for American Society of Gene Therapy; 2006, Co-Chair, Gordon Research
Conference “Drug Carriers in Biology and Medicine”; 1995- co-founder, Board of Directors, Chair, Scientific
Advisory Board, Supratek Pharma, Inc., Montreal, Canada; 2005- co-founder and member, Board of Directors,
CSO, InnovaForm Technologies, LLC, Philadelphia, PA; Editorial Boards: 1997- J. Contr. Release; 1998- J.
Bioact. Comp. Polymers; Editorial Advisory Boards: 1999- The AAPS J. (previously PharmSci); 2000- Adv.
Drug Del. Rev.; 2001- Bioconj. Chem.; 2003- J. Pharm. Sci.; 2005- Int. J. Nanomedicine; 2006- Section Editor,
Drug Delivery and Developmental Therapeutics J. Neuroimmune Pharmacol. Grants review: 1995- NSF,
Petroleum Research Fund, European Science Foundation, Israel Science Foundation, Australian Research
Council, Canada Foundation for Innovation and other agencies; 1999-2003 panels for CAREER awards, NSF
Divisions of Biotechnology/Biochemical Engineering and Material Research/Polymers; 1998-2004 (ad hoc)
National Institutes of Health (NIH) panels Hematology-1 (SBIR/STTR), Research Resources (P41, U-19), Drug
Delivery (chair); 2006-08 chair (2003-06 member) NIH Biomaterials and Biointerfaces study section).
B. Selected Publications (of 187 peer-reviewed papers, 18 book chapters, 6 books/issues edited):
1. Batrakova E.V., Kelly D.L., Li S., Li Y., Yang Z., Xiao L., Alakhova D.Y. Sherman S., Alakhov V.Y.,
Kabanov, A.V. (2006) Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer
cells by a polymer excipient: pluronic P85. Mol. Pharm. 3(2):113-23. PMC2566789
2. Kabanov, A.V. (2006) Polymer genomics: An insight into pharmacology and toxicology of nanomedicines.
Adv. Drug Del. Rev. 58 (15):1597-621. PMC1853357
3. Bronich T.K., Bontha S.A., Shlyakhtenko L.S., Bromberg L., Hatton T.A., Kabanov A.V. (2006) Templateassisted synthesis of nanogels from Pluronic-modified poly(acrylic acid), J. Drug Target. 14: 357-366. PMID:
16919349
4. Litmanovich E.A., Syaduk G.V., Lysenko E.A., Zezin A.B., Kabanov A.V., Kabanov V.A. (2006) Effect of
concentration regime on rheological properties of sodium polymethacrylate and its complexes with polystyrenepoly(N-ethyl-4-vinylpyridinium bromide) block copolymer in aqueous salt solution. Polymer Sci. A 48 (9):997-1003
5. Oh, K.T., Bronich, T.K., Bromberg, L., Hatton, T.A., Kabanov, A.V. (2006) Block ionomer complexes as
prospective nanocontainers for drug delivery, J. Control. Release 115 (1):9-17. PMID: 16919349
6. Sriadibhatla, S., Yang, Z., Gebhart, C., Alakhov, V.Y., Kabanov, A. (2006) Transcriptional activation of
gene expression by pluronic block copolymers in stably and transiently transfected cells. Mol. Ther. 13:804-13.
7. Uversky V.N., Kabanov A.V., Lyubchenko Y.L. (2006) Nanotools for megaproblems: Probing protein
misfolding diseases using nanomedicine modus operandi. J. Proteome Res. 5(10): 2505-22. PMC1880889
8. Batrakova E.V., Shu L., Reynolds A., Mosley R.L., Bronich T.K., Kabanov A.V., Gendelman H.E. (2007) A
macrophage-nanozyme delivery system for Parkinson’s disease, Bioconjug. Chem. 18(5):1498-506.
PMID:17760417
9. Kabanov A.V., Gendelman H.E., (2007) Nanomedicine in the diagnosis and therapy of neurodegenerative
disorders, Progr. Polym. Sci., 32(8-9):1054-82. PMC2386756
10. Chelushkin P.S., Lysenko E.A., Bronich T.K., Eisenberg A., Kabanov V.A., Kabanov A.V. (2007) Polyion
complex nanomaterials from block polyelectrolyte micelles and linear polyelectrolytes of opposite charge: 1.
Solution Behavior. J. Phys. Chem. B. 111(29):8419-25. PMID: 17441751
11. Oh K.T., Bronich T.K., Kabanov V.A., Kabanov A.V. (2007) Block polyelectrolyte networks from poly(acrylic acid) and poly(ethylene oxide): sorption and release of cytochrome C. Biomacromolecules 8(2): 490-7.
PMID: 17291073
12. Solomatin S.V., Bronich T.K., Eisenberg A., Kabanov V.A., Kabanov, A.V. (2007) Nanomaterials from ionic
block copolymers and single-, double- and triple-tail surfactants, J.Phys.Chem. B. 23:2838-42.PMID:17266337
13. Spitzenberger T.J., Heilman D., Diekmann C., Batrakova E.V., Kabanov, A.V., Gendelman H.E., Elmquist,
W.F., Persidsky Y. (2007) Novel delivery system enhances efficacy of antiretroviral therapy in animal model for
HIV-1 encephalitis. J. Cereb. Blood Flow Metab. 27(5):1033-42. PMID: 17063148
14. Batrakova E.V., Kabanov A.V. (2008) Pluronic block copolymers: Evolution of drug delivery concept from
inert nanocarriers to biological response modifiers, J. Control. Release, 130(2):98-106. PMC2575076
15. Chelushkin P.S., Lysenko E.A., Bronich T.K., Eisenberg A., Kabanov V.A., Kabanov A.V. (2008) Polyion
complex nanomaterials from block polyelectrolyte micelles and linear polyelectrolytes of opposite charge: 2.
Dynamic properties, J. Phys. Chem. B., 112(26):7732-8. PMID: 18533694
16. Gilmore J.L. Yi X., Quan L., Kabanov A.V. (2008) Novel nanomaterials for clinical neuroscience, J.
Neuroimmune Pharmacol., (2): 83-94. PMC2566785
17. Li Y., Bronich T.K., Chelushkin P.S., Kabanov A.V. (2008) Dynamic properties of block ionomer
complexes with polyion complex cores, Macromolecules, 41(15):5863-8.
18. Sahay G, Batrakova E.V., Kabanov A.V. (2008) Different internalization pathways of polymeric micelles
and unimers and their effects on vesicular transport. Bioconjug. Chem., 19(10):2023-9. PMCID: PMC2575076
19. Sharma A.K., Zhang Li., Li S., Kelly D.L., Alakhov V.Yu., Batrakova E.B., Kabanov A.V. (2008) Prevention
of MDR development in leukemia cells by micelle-forming polymeric surfactant. J. Control. Release,
131(3):220-7. PMID: 18722489
20. Wang F., Bronich T.K., Kabanov A.V., Rauh R.D., Roovers J. (2008) Synthesis and characterization of
star poly(epsilon-caprolactone)-b-poly(ethylene glycol) and poly(L-lactide)-b-poly(ethylene glycol) copolymers:
evaluation as drug delivery carriers. Bioconjug. Chem. 19(7):1423-9. PMID: 18564869
21. Yang Z., Sahay G., Sriadibhatla S., Kabanov A.V. (2008) Amphiphilic block copolymers enhance cellular
uptake and nuclear entry of polyplex-delivered DNA. Bioconjug. Chem., Epub 2008 Aug 27. PMC2574534
22. Yi X., Batrakova E.V., Banks W.A. Vinogradov S.V., Kabanov A.V. (2008) Protein conjugation with amphiphilic block copolymers for enhanced cellular delivery, Bioconjug. Chem., 19(5):1071-7. PMC2570949
23. Zhang X., Alakhova D.Y., Batrakova E.V., Li S., Yang Z., Li Y., Kabanov A.V. (2008) Effect of Pluronic P85
on amino acid transport in bovine brain microvessel endothelial cells. J. Neuroimmune Pharmacol. 4(1), 35-46.
PMC2644348
24. Gaymalov, Z.Z, Yang, Z, Pisarev, V.M., Alakhov, V.Yu., Kabanov, A.V. (2009) The effect of the nonionic
block copolymer pluronic P85 on gene expression in mouse muscle and antigen-presenting cells, Biomaterials,
30 (6): 1232-45. PMC2667955
C. Research Support:
Ongoing Research Support
COBRE: “Nebraska Center for Nanomedicine”
Principal Investigator: A.V. Kabanov
Agency: NIH
Type: 1P20RR021937-01A2
Period: 09/26/08 – 06/30/13
This proposal seeks to develop an interdisciplinary Nanomedicine Center at the University of Nebraska
Medical Center (UNMC). We have assembled a team of scientists with specific expertise in nanomedicine,
drug delivery, therapeutics and diagnostics. These will now be joined by biochemists, pharmacologists,
immunologists and neuroscientists. All will work, with singular focus, to develop the means to best use devices
of nanoscale size to improve outcomes for cancer, neurodegenerative and cardiovascular diseases. Such
approaches will deliver drugs to focal areas of central nervous system disease or directly to tumors. Parallel
studies seek nanotechnologies to improve diagnostic measures and disease monitoring. Within the Center up
to five junior project leaders are provided with research funds, experienced mentoring, and support of
Bioimaging and Nanomaterial core facilities. The Center also supports recruitment of faculty to UNMC working
in the Nanomedicine field. The long-term goals are to build upon and integrate already strong areas of
research in cancer biology, neurodegenerative disorders, molecular imaging (magnetic resonance and single
photon emission computed tomography) with material and pharmaceutical sciences (nanomaterials, polymers,
drug delivery, and gene delivery). The envisioned cross-disciplinary expertise could be joined between
traditional biomedical research and material sciences through the Center. There is no overlap with any of Dr.
Kabanov’s research projects.
“Polymer based gene delivery”
Principal Investigator: A.V. Kabanov
Agency: NIH NCI
Type: R01 CA116591-04
Period: 5/1/06 – 4/30/11
Co-administration of nonionic poly (ethylene oxide)-poly(propylene oxide) block copolymers (Pluronic) has
greatly increased the trangene expression of the plasmid DNA in the muscle. These block coplymers were
shown to be safe in human clinical trials for cancer chemotheray, which supports their evaluation for possible
use in gene therapy. The objectives of the proposal are 1) to determine most efficient Pluronic compositions for
plasmid DNA delivery in the muscle, 2) to determine the mechanism by which Pluronic enhances transgene
expression, and 3) to evaluate this system for delivery of DNA vaccines targeting malignant melanoma.
"Polypeptide modification for enhanced brain delivery"
Principal Investigator: A.V. Kabanov
Agency: NIH NINDS
Type: RO1 NS051335-03
Period: 2/15/06 - 1/31/10 (no cost)*
The objective of this proposal is to enhance delivery of leptin to the brain to control obesity. The aims (1) use
horseradish peroxidase (HRP) as a model to optimize the covalent modifications of polypeptides with fatty
acids and block copolymers to increase protein permeability across the blood brain barrier (BBB); (2)
determine the mechanism by which these modifications enhance BBB permeability; (3) determine in vivo the
extent of the accumulation by brain of modified HRP and leptin; (4) determine the extent to which modified
leptins retain biological activity after both peripheral administration and direct injection into brain.
"Interactions of Pluronic Block Copolymers in Drug Resistant Cancers"
Principal Investigator: A.V. Kabanov
Agency: NIH NCI
Type: RO1 CA89225-07
Period: 7/01/01-4/30/12
The objective of this proposal is to determine the mechanisms through which Pluronic sensitizes the drug
resistant cancer cells. The aims (1) characterize the effects of Pluronic on ATP levels in resistant and sensitive
cells; (2) identify drug/Pluronic formulations effective against resistant cancers; (3) determine whether the
effects of Pluronic on the energy state of the cell inhibit the functional activity of specific drug resistance
mechanisms; and (4) determine factors important for the efficient delivery of Pluronic to the tumor cells in vivo.
“Non-invasive nanodiagnostics of cancer (NINOC)”
Principal Investigator: A.V. Kabanov
Agency: DoD
Type: USAMRMC 06108004
Period: 4/01/07-04/30/10
This project will develop a platform nanotechnology to deliver imaging and diagnostic agents to the cancer
cells. The hydrophilic polymer nanogels of core-shell morphology are designed to entrap different types of
probes used in SPECT, CT, MR or luminescence detection. The surface of the nanogels is modified with
genetically engineered antibody fragments to target the surface of cancer cells and provide site-specific
delivery of the nanogels to tumors in the body.
“Synthetic Nanovaccines Against Respiratory Pathogens (SYNARP)”
Principal Investigator: A.V. Kabanov
Agency: DoD
Type: W81XWH-09-1-0386
Period: 7/01/09-07/31/09
The overall goal of this proposal is to develop fully synthetic vaccines against respiratory infections using novel
nanotechnology platforms based on safe and degradable adjuvant polymer systems that enhance antigen
presentation and stimulate immunity. The proposal focuses on achieving the following specific technical
objectives: 1) Develop molecular methods for intervention strategies employing novel synthetic nanovaccine
platforms encapsulating DNA and protein/peptide antigens that elicit immune response against influenza
H5N1; 2) Test the efficacy of nanovaccines-based intervention regimens against influenza H5N1 in animal
models.
Completed Research Support (last 3 years)
"Interactions of Block Copolymers in Blood Brain Barrier"
Principal Investigator: A.V. Kabanov
Agency: NIH NINDS
Type: RO1 NS36229-09
Period: 9/15/97 - 6/30/09
The objective of this proposal is to enhance the brain delivery of drugs across the BBB using Pluronic. Using
brain microvessel endothelial cells as an in vitro model of the BBB, and using in vivo tissue sampling in mice,
the aims (1) characterize the mechanism of Pgp inhibition in BBB; (2) examine the extent to which Pluronic
effects can alter other carrier systems in BBB; (3) Examine the extent to which Pluronic can alter vesicular
transport in BBB and, (4) determine how Pluronic affects delivery of drugs to the brain in vivo.
"Structure and Dynamics of Block Ionomer Complexes”
Principal Investigator: A.V. Kabanov
Agency: NSF
Type: DMR-0513699
Period: 6/01/05-5/31/09
The major goal of this project is to explore dispersed composite nanomaterials which represent 1) micelle-like
aggregates with the polyion complex core and hydrophilic; 2) micelles with a hydrophobic cores and polyion
complex corona. The work focuses on the reactions of polyelectrolyte interchange involving these materials
and utilizes variety of experimental and theoretical approaches to determine the rates of these reactions and
understand the contribution of the core-shell architecture to the dynamic properties of these materials.
"Interactions of Pluronic Block Copolymers in Drug Resistant Cancers"
Principal Investigator: A.V. Kabanov
Agency: UNMC Eppley
Type: Cancer Center grant
Period: 11/01/05-2/31/07
Cancer Center
This award by the UNMC Eppley Cancer Center supports the extension of the studies in CA89225-5 to obtain
new preliminary data including evaluation of effects of Pluronic on development of drug resistance in cells and
DNA microarray analysis.
Additional information: 24 US patents awarded.